These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
4. Relapse rate and low serum neuroleptic levels in schizophrenics treated with fluphenazine: another view. Boza RA, Milanes F, Starkey T, Slater V, Dominguez F. J Clin Psychiatry; 1988 Jun; 49(6):245. PubMed ID: 2897960 [No Abstract] [Full Text] [Related]
5. Clinical state and serum neuroleptic levels measured by radioreceptor assay in schizophrenia. Tune LE, Creese I, Depaulo JR, Slavney PR, Coyle JT, Snyder SH. Am J Psychiatry; 1980 Feb; 137(2):187-90. PubMed ID: 6101524 [Abstract] [Full Text] [Related]
6. Correction of serum neuroleptic activity for blood-to-brain distribution: a method that may render radioreceptor assay results comparable between neuroleptics. Young AS, Faraone SV, Brown WA. J Clin Psychopharmacol; 1989 Oct; 9(5):361-3. PubMed ID: 2571620 [Abstract] [Full Text] [Related]
7. Neuroleptic concentrations in schizophrenic patients: measurements by radioreceptor assay and gas chromatography. Javaid JI, Davis JM, Dysken MW, Janicak P, Casper R. Psychopharmacol Bull; 1983 Oct; 19(1):72-4. PubMed ID: 6131469 [No Abstract] [Full Text] [Related]
8. Early neuroleptic intervention in schizophrenia: are prodromal symptoms valid predictors of relapse? Gaebel W, Frick U, Köpcke W, Linden M, Müller P, Müller-Spahn F, Pietzcker A, Tegeler J. Br J Psychiatry Suppl; 1993 Sep; (21):8-12. PubMed ID: 8105814 [Abstract] [Full Text] [Related]
9. Neuroleptic-resistant schizophrenia treated with clozapine and ECT. Benatov R, Sirota P, Megged S. Convuls Ther; 1996 Jun; 12(2):117-21. PubMed ID: 8744173 [Abstract] [Full Text] [Related]
12. [Blood levels of neuroleptics required to prevent recurrence--a radioreceptor assay]. Nakahara Y, Morioka T, Yokota N, Sarai K, Fukuchi T. Seishin Shinkeigaku Zasshi; 1986 Jun; 88(11):944-51. PubMed ID: 2883692 [No Abstract] [Full Text] [Related]
13. [Cortical atrophy in MRI, mental status and neuroleptic treatment effect in schizophrenia]. Jarema M, Choma M, Kozłowski P, Poniatowska R, Krawczyk R. Psychiatr Pol; 1997 Jun; 31(5):547-57. PubMed ID: 9547181 [Abstract] [Full Text] [Related]
14. Neuroleptic blood levels in outpatient maintenance therapy of schizophrenia. Sajadi C, Smith RC, Shvartsburd A, Morton V, Mirabi M, Gordon J. Psychopharmacol Bull; 1984 Jun; 20(1):110-3. PubMed ID: 6144129 [No Abstract] [Full Text] [Related]
15. [Dynamics of the serum pipothiazine level in patients with schizophrenia during long-term treatment with this neuroleptic agent]. Lipska B, Szukalski B, Nurowska K, Welbel L. Psychiatr Pol; 1987 Jun; 21(1):14-9. PubMed ID: 2887001 [No Abstract] [Full Text] [Related]
19. An early phase II clinical trial of remoxipride in schizophrenia with measurement of plasma neuroleptic activity. Chouinard G, Turnier L. Psychopharmacol Bull; 1986 Jun; 22(1):267-71. PubMed ID: 2873615 [No Abstract] [Full Text] [Related]
20. [Initial clinical response to neuroleptic treatment and serum prolactin levels in acute schizophrenic psychoses]. Fuentenebro de Diego F, Cabranes JA, Ramos Brieva J, López Jiménez MR, Santiesteban Requena C. Actas Luso Esp Neurol Psiquiatr Cienc Afines; 1981 Jun; 9(6):499-506. PubMed ID: 6129779 [No Abstract] [Full Text] [Related] Page: [Next] [New Search]